Research.Patient.info
Intermediate-risk Non-muscle Invasive Bladder Cancer research hub
2 indexed studies · 2 currently recruiting
- recruitingPhase I and Phase II (Integrated)- Other
A clinical study of sacituzumab tirumotecan (sac-TMT) in people with bladder cancer (MK-2870-027)
This clinical trial is testing a new drug called sacituzumab tirumotecan (sac-TMT) in adults with intermediate-risk non-muscle invasive bladder cancer. Doctors want to see how safe the medicine is, what dose works best, and how well it helps stop bladder cancer from returning or growing.
Spain · France · Netherlands - recruitingPHASE3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
This study is testing a new gene therapy, Nadofaragene Firadenovec, for people with a type of bladder cancer called intermediate-risk non-muscle invasive bladder cancer. It compares the new treatment to simply monitoring the cancer to see if it helps prevent recurrence.
United States · Canada · Czechia